Remove Immune Response Remove Licensing Remove Science
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

The development of CAR T-cell technology is a defining moment in the history of biomedicine one of the all-time amazing transformative breakthroughs, demonstrating how bold ideas in basic science can evolve into lifesaving therapies, said Richard Merkin, M.D., We treated our first patient with CD19 CAR T cells back in 2007.

Therapies 119
article thumbnail

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech

The Pharma Data

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing its Shigella vaccine candidate, altSonflex1-2-3 , to Bharat Biotech International Limited (BBIL).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. The FDA’s action applies to therapies made by Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson and Novartis that are used to treat several types of blood cancer.

Therapies 178
article thumbnail

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

The Pharma Data

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. About Gilead Sciences. Gilead Sciences, Inc.

Vaccine 52
article thumbnail

Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine

The Pharma Data

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

article thumbnail

Lead Pharma Teams with Roche on Oral Small Molecules for Immune-Mediated Diseases

The Pharma Data

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Humans as well as cats and dogs can be affected. .

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

from 2003 to 2006, covering the biotechnology and life-science tools sectors. Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. gammadelta T cells link innate and adaptive immune responses.

Therapies 105